GSK Lamictal monotherapy for seizures
Executive Summary
GlaxoSmithKline's Lamictal (lamotrigine) approved by FDA Jan. 14 for use as monotherapy in the treatment of partial seizures in patients 16 years and older. Originally approved in December 1996 as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, Lamictal has been part of GSK's plan to fill in its nearer-term pipeline through line extensions (1"The Pink Sheet" Dec. 15, 2003, p. 29)...